Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Comparing radiofrequency treatment and corticosteroid injection for hip osteoarthritis pain

Official title: Continuous Radiofrequency in Hip Osteoarthritis Pain: A Protocol of a Randomized Clinical Trial

Run by University of Brasilia · NCT06221709 · Data updated 2026-11-12

This study is testing whether a new radiofrequency treatment works better than a steroid injection for relieving pain and improving movement in people with hip osteoarthritis.

More Hip Osteoarthritis trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment70 (estimated)
SponsorUniversity of Brasilia
Academic / other
Locations1 site (Brasília, Federal District)
StatusRecruiting
StartedFebruary 1, 2024
Main results expectedAugust 31, 2026
Study endsApril 30, 2027
Registry record updatedJanuary 24, 2024
Trial IDNCT06221709 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are individuals aged 18 and older with symptomatic unilateral hip osteoarthritis grades II and III, experiencing pain for more than six months.

Probably not a fit

Patients with specific exclusions such as radiculopathy, previous hip surgeries, or other significant medical conditions may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial is designed to evaluate the effectiveness of Conventional Radiofrequency (CRF) treatment compared to intraarticular corticosteroid injection in managing pain and improving function in patients with hip osteoarthritis. The study will be conducted at Hospital SARAH in Brasília, utilizing a double-blinded, randomized approach to ensure unbiased results. Participants will undergo sedation or general anesthesia, and the procedures will be performed under fluoroscopic guidance to ensure accurate placement of the treatment. The trial aims to provide insights into the best pain management strategies for individuals suffering from this condition.

Why it matters

Potential benefit: If successful, this study could provide a more effective pain management option for patients with hip osteoarthritis.

How similar studies have gone: Other studies have shown promising results with similar approaches, indicating potential for success in this trial.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Individuals ≥ 18 years of age, with symptomatic unilateral hip osteoarthritis, grades II and III according to the Kellgreen and Lawrance classification, hip pain for more than six months (medial, anterior, anterolateral, and/or lateral region) will be included.

Exclusion Criteria:

* Individuals with radiculopathy and ipsilateral irradiation, osteonecrosis of the femoral head, previous arthroplasty on the hip to be studied or surgical scar that could lead to changes in the anatomy of the hip, cases of high dislocation of the hip, pain exclusively in the posterior region, symptomatic ipsilateral knee osteoarthritis, intra-articular infiltration of corticosteroids or hyaluronic acid in the hip for less than six months, patients with neurological diseases, peripheral neuropathy or psychiatric diseases, use of a pacemaker or Prothrombin Activity Time (INR) \> 3.

Where it's running

  • Rede Sarah Hospitais de Reabilitação
    Brasília, Federal District, Brazil
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.